Trial
NCT04926831
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
capmatinib
Why stopped
The study was terminated early due to recruitment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-16